Alimta drug research

The study at the Northern Institute for Cancer Research will develop tests of mesothelioma samples to find out which patients will benefit from the drug pemetrexed (Alimta) in combination with a platinum drug.

The research will help to understand why only some people with mesothelioma respond to Alimta. This will help establish at the time of diagnosis whether a patient is likely to respond or whether they should be offered an alternative treatment.

The data collected will help to identify what makes mesothelioma resistant to treatment and therefore direct new research into new drugs to treat the disease.

The research will be supervised by the Centre’s Director, Professor Hilary Calvert who led the team that develop Alimta If successful it will make the treatment more cost effective, one of the issues concerning NICE decision while giving those suffering from the illness a much better quality of life for longer.

Source - Mesothelioma research

To contact one of our specialist lawyers please call 0800 61 66 81, or use the contact details at the top left of this page.